DALLAS, June 22, 2015 /PRNewswire/ --
Global HPV Testing Market 2015-2019 research report calculates market size by using revenue generated from the sales of HPV testing kits and detection systems and highlights Abbott Diagnostics, Hologic Inc., and Qiagen NV as three major companies of the market.
Complete report on HPV testing market spread across 65 pages, talking about 4 major companies and supported with 25 exhibits is now available at http://www.reportsnreports.com/reports/402774-global-hpv-testing-market-2015-2019.html .
HPV and Pap tests help detect cervical cancer in women. The Pap test identifies changes in cervical cells caused by HPV infection, and the HPV test is used to check for HPV DNA in sample cells. A physician may advise a patient to undergo both HPV and Pap tests for the screening of cervical cancer. Over the past few years, there has been a change in the way the disease is managed by healthcare organizations and individuals. Efficient disease management is driven by increased purchasing power of customers and the availability of innovative healthcare products in the market. This report covers the present scenario and growth prospects for the global HPV testing market from 2015-2019.
This HPV testing market research analyses the solutions and products offered by market vendors and presents a comprehensive breakdown in terms of market segmentation by key geography, including the Americas, EMEA, and the APAC region. Increased incidence of HPV and growing prevalence of cervical cancer are the major HPV testing market growth drivers discussed in this research. Co-testing with HPV and pap tests as well as emergence of HPV primary screening tests are the major trends while lack of public awareness and alternative diagnostic tests for cervical cancer are the HPV testing market challenges for the industry players.
Companies mentioned in this HPV testing market 2015 research report include Abbott Diagnostics, Hologic, Qiagen, Roche Diagnostics, Arbor Vita, Becton, Dickinson and Company, Cepheid, Delphi Bioscience, DiaCarta, Diasorin, Fujirebio, Genera Biosystems, IncellDx, OralDNA Labs, Quest Diagnostics, Seegene, Trovagene and Ventana Medical Systems. Order a copy global HPV testing market 2015-2019 research report at http://www.reportsnreports.com/Purchase.aspx?name=402774 .
For reports by Technavio / Infiniti Research Limited, ReportsnReports.com is running a special offer wherein 3 reports can be purchased at the cost of 2 (lowest priced report will be free) or if the reports are of same price, pay for 2 and get the third report free. If you order 4 or more reports in a single order, you get 50% flat discount on the total pricing. To avail this offer, send an email to firstname.lastname@example.org with your market research reports requirements or call us on +1 888 391 5441 to avail this offer.
On a related note, ReportsnReports.com offers another research titled Cervical Cancer Screening Market by Test Type (PAP, HPV), Kit Type (PAP, HPV), End User (Hospitals, Laboratories, Physicians' Offices & Clinics) - Global Forecast to 2020 spread across 200 pages and published in March 2015. Rising prevalence rate of cervical cancer, high incidence rate of HPV infection, increasing number of awareness programs and government initiatives and funding are forecast to drive growth of the microscopy market. Developing markets such as Middle East, Brazil, Argentina, Mexico, China, India, and Malaysia are lucrative markets for global cervical cancer screening, owing to favorable government incentives and corporate funding. Growth in aging female population and rising prevalence rate of cervical cancer, high incidence rate of HPV infection, increasing number of awareness programs cervical cancer screening, and government initiatives and funding are propelling the growth of these segments. Laboratories segment is the major end users of the global cervical cancer screening market in 2014. New and innovative product launches, acquisition and strategic alliances was found to be a dominant strategy adopted by key industry participants to increase their market share and cater to the unmet market needs. Companies profiled in this cervical cancer screening market research include Hologic, Inc., Qiagen N.V., Roche Diagnostics, Quest Diagnostics, Oncohealth Corporation and Femasys, Inc. Order a copy of Cervical Cancer Screening Market by Test Type, Kit Type, End User and Global Forecast to 2020 research report at http://www.reportsnreports.com/Purchase.aspx?name=351709 .
Third research titled Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2015 market report provides comprehensive information on the therapeutic development for Human papillomavirus (HPV) Associated Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Human papillomavirus (HPV) Associated Cancer and special features on late-stage and discontinued projects. Spread across 121 pages, this report talks about companies like 3SBio Inc., Abivax, Admedus Ltd, Antigen Express, Inc., Bionor Pharma ASA, Cancer Therapeutics CRC Pty Ltd, Etubics Corporation, EyeGene, Inc., Formune S.L., Genexine, Inc., iBio, Inc., Inovio Pharmaceuticals, Inc., MedImmune, LLC, Merck & Co., Inc., Novartis AG, Onconova Therapeutics, Inc., Prima BioMed Ltd., Profectus BioSciences, Inc., Redbiotec AG, Sirnaomics, Inc., Theravectys S.A., Transgene SA, Vaccibody AS, Virometix AG and ViroStatics, SRL. Drug profiles covered in this HPV research include ABX-318, AEH-10p, alpelisib, Antibodies to Target E6 for HPV Associated Cancer, Antibodies to Target E7 for HPV Associated Cancer, Cell Therapy to Target HPV-16 E6 Protein for Papillomavirus Associated Cancers, durvalumab + tremelimumab, EDA-HPVE7, EG-HPV, Gene Therapy for Papillomavirus Associated Cervical Carcinoma, GX-188E, HPV Vaccine, human papillomavirus (7-valent) vaccine, human papillomavirus (9-valent) vaccine, human papillomavirus [Serotype 16] vaccine, human papillomavirus vaccine, human papillomavirus vaccine [types 6, 11, 16, 18] biosimilar, INO-3106, INO-3112, Peptide to Inhibit HPV E6 Protein for HPV Associated Cancer, RBT-201, rigosertib sodium, Small Molecule to Inhibit CDK9 for HPV Associated Cancers and Warts, Small Molecules to Inhibit Ubiquitin E3 Ligase E6AP for Cancer, SSS-08, STP-909, STP-911, TG-4001, Vacc-HPV, Vaccine for HPV Associated Cancer, Vaccine for HPV Associated Head and Neck Cancer, Vaccine for HPV Associated Skin Cancer, Vaccines for HPV Associated Cervical Cancer, VB-1016 and Vicoryx. Read more at http://www.reportsnreports.com/reports/344881-human-papillomavirus-hpv-associated-cancer-pipeline-review-h1-2015.html .
Explore more reports on healthcare market and pharmaceuticals industry at http://www.reportsnreports.com/market-research/pharmaceuticals/ .
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
Connect With Us on:
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252